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Abstract The aim of the study was to compare device
life of more recent indwelling voice prostheses Provox
Vega and Blom-Singer Dual Valve to device life of well-
known standard devices (Provox 2, Blom-Singer Classic).
In a prospective, non-randomised study, device life of
Blom-Singer Classic, Blom-Singer Dual Valve, Provox2,
Provox Vega and Provox ActiValve voice prostheses was
recorded in a group of 102 laryngectomised patients. In
total 749 voice prosthesis were included. Average overall
life time was 108 days, median 74 days. The prosthesis
with the longest dwell time was the Provox ActiValve
(median 291 days). Provox Vega had longer device life
compared with Provox2 (median 92 days vs 66 days;
p = 0.006) and compared with Blom-Singer Classic
(median 92 days vs 69 days; p = 0.004). In conclusion,
device lifetimes of Provox Vega and ActiValve were
better than those of Provox2 and the Blom-Singer Classic.
New voice prostheses, with a defined valve opening
pressure (Provox Vega, Provox ActiValve, Blom-Singer
Dual Valve) had longer lifetimes than prostheses without a
defined opening pressure (Blom-Singer Classic and
Provox 2).
Keywords Laryngectomy  Device life time  Voice
prosthesis  Provox Vega  Blom-Singer
Introduction
In 1982, the first indwelling voice prosthesis, the ‘‘Gron-
ingen Button’’ was introduced [1]. From then on, the
indwelling concept of voice restoration became the gold
standard of tracheoesophageal voice restoration in indus-
trial nations as it allows supplying also older and less
skilful patients with voice prostheses [1]. Disadvantages of
the indwelling concept are the need for a physician or a
speech language pathologist (SLP) to change the voice
prostheses and the need for a placement tool. Moreover, the
device life of indwelling voice prostheses is largely
dependent on patients and prosthesis factors (e.g. speaking
habits, diet, biofilm resistance, underpressure, valve fea-
tures) and cannot be improved by cleaning strategies as
they are not cleaned on a daily basis similar to non-
indwelling devices. Placement tools became more and
more sophisticated over the years, evolving from retro-
grade placement (Provox 1 1990, Groningen ULR) [2] to
anterograde placement (Blom-Singer Classic with a Gel
Cap, Provox 2 with an inserter) [3, 4] and most recently to
exactly controlled anterograde placement with the third-
generation Provox Vega with the SmartInserter [5] and the
Provox Vega Puncture Set (for all-in-one surgical creation
of the TE puncture and placement of the voice prosthesis)
[6]. In Germany indwelling voice prostheses with an
anterograde insertion method and a rational cost/lifetime
ratio became standard devices (Provox 2, Blom-Singer
Classic). Due to patient comfort, safety and economical
aspects, in the past years, several voice prostheses with
additional features intended to prolong device life have
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become available. The Blom-Singer Advantage with a
valve flap containing 7 % of silveroxide for patients with
premature device failure due to biofilm formation coloni-
sation [7, 8] and the Blom-Singer Dual Valve that incor-
porates two valve flaps containing silveroxide in the shaft
of the device (no clinical data are currently available for
this device), and the Provox ActiValve in which the valve
flap and valve seat are constructed out of fluoroplastic and
valve flap closure is supported by magnets for patients with
early device failure due to biofilm formation and/or un-
derpressure in the oesophagus during swallowing and/or
inhalation [9]. In addition to these design changes, newer
voice prostheses (Blom-Singer Dual Valve, Provox Vega
and ActiValve) have also been found to have more defined
opening pressures, which may lead to differences in device
life [10].
Besides ease of phonation, overall voice quality and
patient preference, device lifetime is an important param-
eter measured in several studies comparing different voice
prostheses. It is generally considered an important factor
from a cost perspective; the shorter the device life, the
higher the consumption of prostheses and hospital visits.
Studies to date have revealed that, on average, the
device life of a standard indwelling voice prosthesis falls
somewhere between 4 and 6 months for the majority of
patients [2, 11–14]. However, significant variations in
device life have been reported within patients, between
different patient groups, and across device types, influ-
enced by reflux, nutrition and geographical regions [15,
16]. Our study can rule out effects of different patient
groups and allows comparison of device life time without
the influence of socioeconomic and reimbursement aspects
[15, 16]. Device life of the Provox2 has been studied in a
variety of studies and often serves as a reference for
comparison with other studies and other types of voice
prostheses [2, 12–14]. The device life of the Provox Ac-
tiValve has been shown to be substantially longer than that
of the traditional indwelling voice prostheses [9, 17, 18].
Also the Blom-Singer Advantage (model with hard valve
assembly) has been shown to have a longer device life in
selected patients [7, 8]. Published results regarding the
device life of the Provox Vega have mainly covered short
observation periods and were found to be similar to the
device life of Provox2 [15, 16]. However, one long-term
study from Australia indicates that the Provox Vega may
have a rather long device life, at least in the Australian
setting [19]. To our knowledge no device life data have
been published yet regarding to the Blom-Singer Dual
Valve. To date, very few studies have investigated differ-
ences in device life between the various indwelling devi-
ces, and the outcomes have not shown large differences,
except for the Provox ActiValve, compared to the standard
indwelling devices [20–23].
The most common reason for replacement of an
indwelling device is leakage through the device. Other
reasons for replacement are for example the need for size
changes, increased speaking effort, granulation tissue and
inflammation/infection (‘device-related’ reasons) [12, 22].
Reasons for diversity in device life duration such as
patient- and treatment characteristics as well as socioeco-
nomic and reimbursement aspects are also focus of
research [19].
In our centre a variety of voice prostheses from different
manufacturers is being used to meet each patient’s indi-
vidual needs. Since device life is an important factor in
clinical and economical decision making, the aim of our
prospective study was to investigate and compare the
device life of five different indwelling devices used at our
institute with a special focus to compare the newer devices
(Provox Vega and Blom-Singer Dual Valve) to standard
prostheses used in our institution.
Subjects and methods
Subjects
All laryngectomised patients visiting the outpatient clinic
of our hospital between November 2009 and November
2012 for a voice prosthesis change were entered in the
study if they consented to the study and data privacy pro-
tocol. A total of 749 voice prosthesis replacements were
included from a group of 102 laryngectomised patients.
Ages ranged from 42 to 86 years, with a median of
64.4 years in female and 61.2 years in male patients (See
Table 1).
Patients were seen by one of the 17 physicians tending
the outpatients of one centre in Trier, Germany. The phy-
sicians had different levels of experience, and five different
voice prostheses (Provox2, Provox Vega 22.5 Fr, Provox
ActiValve, Blom-Singer Classic Indwelling 20 Fr, Blom-
Singer Dual Valve 20 Fr) were used. Excluded were cases
where the device failed due to ‘‘patient/puncture related
reasons’’ (e.g. puncture infection, size changes and dislo-
cation of the prosthesis). Also excluded were the first
prostheses used intraoperatively, since it is known that their
service life can be disproportionately long [2, 24]. Included
were cases where the device failed due to ‘‘prostheses
related reasons’’ (e.g. leakage through the device, high
pressure speech, and biofilm growth on the outside of the
shaft). Leakage of the valve was assumed when reported by
the patient or when it was detected during a swallowing test
(three swallows of clear water over a period of 2 min).
All voice prostheses were used in accordance with the
manufacturer’s recommended use of the device and the
manufacturer’s recommended insertion method. The
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following algorithm of prosthesis choice is generally
accepted and applied in our institution: Provox 2, Provox
Vega and Blom-Singer Classic are used as standard devices
by choice of the doctor using the device based on his
experience and patients requirements (e.g. stoma size,
place of TE puncture, preferred insertion method, need for
overshooting, speaking problems). If a standard device
shows a reduced device life \6 weeks more than two
times, a moderately expensive special prosthesis is used
(Blom-Singer Dual Valve, hard valve assembly). Does
device life improve to 3 months or more without negative
side effects (e.g. speaking problems), the patient is con-
secutively fitted with this type of voice prosthesis. If life-
time does not improve to at least 2 months, the patient is
considered to be fitted with the effective but also expensive
Provox ActiValve. At the time the voice prosthesis had to
be removed, the life of the voice prosthesis was calculated
in days, the type of prosthesis was listed and the history
was checked to exclude that in the meantime no undocu-
mented voice prosthesis change (e.g. during emergency
services) had taken place.
Short description of each device
Blom-Singer Classic (20 French (Fr) and 16 French),
Inhealth Technologies, Carpinteria, CA, USA
This soft and flexible voice prosthesis is entirely made out
of silicone, with a flap valve incorporated in the shaft. The
outer ring of the oesophageal flange is radiopaque. The
shaft diameter used in our clinic is 20 Fr. It is inserted
anterograde, with a gel cap. It is used in our clinic as a
standard prosthesis and for the management of complica-
tions as it is available in oversized shaft lengths (up to
30 mm). See Fig. 1a.
Blom-Singer Dual ValveTM, Inhealth Technologies,
Carpinteria, CA, USA
The Blom-Singer Dual Valve has a silicone housing and
two silicone flap valves containing 7 % of silveroxide
mixed into the silicone, one on the oesophageal side, and
an additional one on the tracheal side. The double valve is
intended to increase the lifetime, because it is assumed that
the second valve will prevent leakage after the first valve
fails. In addition, the silveroxide is expected to have anti-
fungal properties. Speaking pressures and valve opening
pressures of the Blom-Singer Dual Valve are reported to be
higher than in the Blom-Singer Classic 20 Fr. Blom-Singer
Dual Valve prostheses were used with 20 Fr shaft diameter
and inserted with the gel cap method. See Fig. 1b.
Provox 2, Atos medical, Ho¨rby, Sweden
The Provox2 voice prosthesis is made out of medical grade
silicone, with a radiopaque valve seat made out of fluoro-
plastic, and a silicone flap valve. The device is inserted
anterograde with an inserter pin and loading tube. The
outer diameter is 22.5 Fr. This prosthesis came on the
market in 1997 and has been used in our clinic as a stan-
dard prosthesis since it was first introduced. See Fig. 1c.
Provox VegaTM 22.5, Atos Medical, Ho¨rby, Sweden
The Provox Vega prosthesis is the technically improved
successor of the Provox2 prosthesis. It is specifically
designed to have good airflow characteristics and precise
valve characteristics. The tracheal flange is oval, designed
to better fit the tracheal anatomy and prevent prosthesis
rotation. The safety strap is attached originating in a 90
angle from the tracheal flange as in the Provox1 to
Table 1 Patient characteristics




























Range 3 months–23 years
Median 6.8 years
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eliminate the risk of tracheal mucosa injuries and granu-
lation. It is available in three outer diameters (17 Fr, 20 Fr
and 22.5 Fr). In the present study the 22.5 Fr was used
because it has the best aerodynamic properties. The valve
of the Provox Vega is designed so that it opens in a defined
opening pressure range and unintended valve openings
(e.g. during inspiration) can be reduced [10]. The Provox
Vega comes preloaded in a new insertion system (Smar-
tInserterTM). The SmartInserter prevents unintentional
overshooting (placing the entire prosthesis in the oesoph-
agus) which saves physician and patient unpleasant flange
repositioning procedures. See Fig. 1d.
Provox ActiValveTM, Atos Medical, Ho¨rby, Sweden
The Provox ActiValve voice prosthesis was developed with
the aim of solving problems in a select patient group that is
experiencing extremely short device lifetimes due to
excessive biofilm growth or underpressure in the oesoph-
agus during swallowing or inhalation. The prosthesis has a
housing of medical grade silicone, similar to the Provox2.
Both the valve seat and the valve flap are made out of
fluoroplastic, using magnets available in three different
strengths to support valve closure. Outer diameter and
available lengths are equal to Provox2. Due to significantly
higher costs of the ActiValve, it is only used in our clinic
for the management of extremely short device life. In the
current study, we have provided patients a Provox ActiV-
alve when their voice prosthesis three times in a row had a
life of 40 days or less, the shaft length of the prosthesis was
always the same and there was no trachea-oesophageal
(TE) puncture pathology. In general, the magnetic strength
‘‘strong’’ was selected. If the patient experienced speech
difficulties, we changed to the strength version ‘‘light’’. If
the patient was still experiencing air filling of the stomach
or a short device life time, we changed to ‘‘extra strong’’.
Provox ActiValve users in our clinic are advised that if the
device is still in situ after 1 year, it should be replaced
regardless of whether it is leaking or not. See Fig. 1e.
Statistical analysis
Non-parametric tests (Mann–Whitney) were used to com-
pare the median device lifetimes in days. Median lifetimes
a b
c d e
Fig. 1 Voice prostheses (Photos courtesy of Dr. P Kress) a Blom-Singer Classic b Blom-Singer Dual Valve c Provox2 d Provox Vega
e Provox ActiValveTM
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are more informative compared to means, as suggested by
Op de Coul et al. [12]. Boxplots and Kaplan–Meier sur-
vival curves were created to show the lifetimes. A logrank
test (Mantel–Cox) was used to compare the devices overall,
truncated at 1 year, 6 and 3 months. For all analyses, we
used SPSS version 19.0 and significance was set at
p \ 0.05.
Results
In total, 749 voice prostheses were included, used by 102
patients; 108 Blom-Singer Classic Indwelling, 62 Blom-
Singer Dual Valve, 424 Provox2, 117 Provox Vega, and 38
Provox ActiValve. Per device, the mean and median were,
respectively: Blom-Singer Classic 86/69 days, Blom-
Singer Dual Valve 104/75 days, Provox2 98/66 days,
Provox Vega 107/92 days and Provox ActiValve
298/291 days (See Fig. 2).
Provox2 was the most frequently used voice prosthesis
(62 %), because this prosthesis was the only Provox stan-
dard prosthesis in the beginning of this study. During the
study period the Provox2 got more and more replaced by
the Provox Vega. The prosthesis with the longest dwell
time was the Provox ActiValve; this device appeared to
have at least three times longer lifetimes compared to the
other devices, and its device life time was significantly
longer than any of the other standard voice prostheses
(P \ 0.0001).
When comparing the medians within the groups, Provox
ActiValve had significantly longer lifetimes compared to
all other prostheses (p \ 0.001). In the group of standard
voice prostheses the Provox Vega had significant longer
lifetimes compared to Provox2 (p = 0.006) and compared
to Blom-Singer Classic (p = 0.004). There was no signif-
icant difference between the device life of Blom-Singer
Classic versus Provox2 (p = 0.604), Blom-Singer Dual
Valve versus Provox2 (p = 0.233) and versus Provox Vega
(p = 0.159). (See table accompanying Fig. 2).
Prostheses with a defined valve opening pressure (Blom-
Singer Dual Valve, Provox Vega and ActiValve) had
longer lifetimes than prostheses without a defined opening
pressure (Blom-Singer Classic and Provox 2).
Figure 3 shows the Kaplan–Meier curve of the lifetimes
per device, logrank p \ 0.001. When removing Provox
ActiValve out the analysis, the logrank truncated at 1 year,
6 and 3 months was, respectively, p = 0.181, p = 0.088
and p = 0.024. Provox Vega appeared to have significant
longer lifetimes compared to Provox2, truncated at 1 year
(p = 0.133), 6 months (p = 0.024) and 3 months
(p = 0.005), and compared to Blom-Singer Classic, trun-
cated at 1 year (p = 0.043), 6 months (p = 0.022), and at
3 months (p = 0.006) (Fig. 3).
Discussion
Among 102 patients, in total 749 voice prostheses were
included. The average life time for all devices was
108 days, median 74 days (logrank p \ 0.001). The pros-
thesis with the longest dwell time was the Provox ActiV-
alve. Most interesting for the clinical use, the Provox Vega
showed to have a significantly longer lifetime compared to
Provox2 and to Blom-Singer Classic. Therefore, we rec-
ommend changing from Provox 2 to Provox Vega when-
ever possible. Prostheses with a defined valve opening
pressure (Blom-Singer Dual Valve, Provox Vega and Ac-
tiValve) had longer lifetimes than prostheses without a
defined opening pressure (Blom-Singer Classic and Provox
2). This underlines the importance of aiming to prevent
unintended valve flap openings during inspiration by using
a voice prosthesis with a defined valve opening pressure if
a long device life is intended.
Compared to other studies [2, 12–14], the current study
shows an overall relatively short device lifetime for the
‘standard’ (Provox2, Provox Vega, Blom-Singer Classic)
devices used in our patient population (on average
3.2 months instead of 4–6 months). This is most likely due
to the fact that prostheses are removed in our clinic at the
very first signs of valve failure and patients are trained not
to tolerate any leakage. Moreover, an overrepresentation of
devices with a short lifetime during the observation period
may be present. The data for this study were collected
November 2009 and November 2012 and all replacements
during this time frame are included in the analyses.
Therefore patients with short device life have contributed
several devices to the sample whereas patients with a long
device life only 1 or 2 devices. We do however believe that
our data display clinical reality more precisely than others,
as they are based on a medically safe definition of leakage
and economic effects can more or less be ruled out (patients
do not pay for their prostheses on an individual basis).
The long device life of the Provox ActiValve in comparison
with the ‘standard’ devices is in concordance with other
studies [9, 17, 18]. This is not surprising as this device is
considered a ‘problem-solver’, specifically developed for
laryngectomised patients with early device failure. This
device is priced higher than the standard voice prostheses.
Despite the higher costs, the use of this device could be cost-
effective not to mention the positive effect on patient safety
and comfort. The actual observed lifetime of the ActiValve
may be even longer than the average of 298 days or median of
291 days reported in our study (compared to median 337 days
reported by Soolsma et al. and a mean of 300 days reported by
Graville et al. [17, 18]), as in our clinic this device is usually
changed prophylactically if it is still in situ at 1 year to prevent
biofilm colonisation of the TE puncture and not because of
valve defects. Our results show that in comparison with the
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other devices used, the lifetime of the Provox ActiValve was
about three times longer. Keeping in mind that this device is in
our clinic used in patients with a very short device life (i.e.
about 1 month), it can be expected that—as in the literature
[9]—also in our setting a 14–16-fold increase in lifetime is
found when compared within the same patient.
This is the first study to report on device life of the
Blom-Singer Dual Valve. In our clinic, the Blom-Singer
Dual Valve was used to address early device failure. Our
results did not reveal a significant difference between the
device life of the Blom-Singer Dual Valve (median
75 days) and the Blom-Singer Classic (median 69 days,
p = 0.202), or the Provox2 (median 66 days, p = 0.233),
or the Provox Vega (median 92 days, p = 0.159). But
similar to the Provox ActiValve, this device was used in
patients with short device life ([2 subsequent short device
life) and as such, if the average were compared within the
same patient, an improvement in device life may be found.
Comparison with results for the Provox ActiValve (median
291 days, p \ 0.001), shows a markedly shorter device life
which is in concordance with its lower valve opening
pressure and price. The device life of the Blom-Singer
Dual Valve in our study also seems to be somewhat lower
than the device life reported in previous investigations with
the Blom-Singer Advantage (Kress: mean 101, median
87 days, Leder: mean 118–168 days) [7, 8].
The average device life for Provox2 devices was com-
pared to the literature quite low (mean 88 days versus
111–163 days in four comparable studies) [12, 13, 25, 26].
However, another German retrospective study conducted
from 1993 to 1999 analysed the device life for amongst
others Provox2, where the 96 days on average was nearly
equal compared to our observation [24]. These findings
could be explained by the above mentioned strict definition
BS-Classic BS-DV Provox2 Provox Vega Provox AV Total
Mean (sd) 85.8(70.6) 104.1(88.2) 97.8(127.4) 106.8(80.6) 298.2(155.8) 108.1(121.2)
Range 7-397 6-387 1-1,974 3-478 5-786** 1-1,974
Median 69.0°°° 75.0°°° 66.0°°° 92.0°° 291.0° 74.0
BS-Classic: Blom-Singer Classic 20; BS-DV: Blom-Singer Dual-Valve; Provox AV: Provox ActiValve
** Patients were advised that if the device was still in situ after one year, it should be replaced regardless 
of whether it is leaking or not, however, some patients decided to wait until the device started leaking. 
Non-parametric Mann Whitney U tests on medians: ° Provox ActiValve versus all groups: p<0.001; °°
Provox2 and Blom-Singer Classic versus Provox Vega: p<0.05, °°°Blom-Singer Classic versus Provox2; 
Blom-Singer Dual Valve versus Provox2; Blom-Singer Dual Valve versus Provox Vega: ns.
Fig. 2 Boxplots with device
lifetimes, all prostheses (this
graph has been cut off at
400 days to enhance visibility)
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of leakage, the easy available health care provider in
Germany, and the almost non-existing economic impact on
the patient that asks for a new prosthesis.
The Provox Vega having longer life times compared to
Provox2 is a new finding in the current study compared to
some of the previous literature [15, 16, 23]. These previous
studies covered short observation periods, whereas the
current study covers a long observation period, allowing
more time to observe longer dwell times of the different
devices. This is confirmed by a long-term (2 years) device
life study on Provox Vega devices in an Australian setting,
which reported a median of 222 days and an average of
207 days. These dwell times are considerably longer than
those reported in our study, (median of 92 days and aver-
age of 107 days), which might be explained by health
economical and geographical differences [19].
The device life of the Blom-Singer Classic found in our
study was also quite low compared to others. A mean 68
versus 107 days in a study reported by Schafer et al. and
143.5 days reported by Trussart et al. [20, 24]. This could
be due to the fact that Blom-Singer Classic prostheses are
frequently used for the management of puncture compli-
cations and might in some cases have not been correctly
eliminated from the data pool.
A limitation of the current study is that it was not pos-
sible to compare lifetimes for the different devices within
the same patient. In our setup, one patient could have used
several different devices, or only one type of device, based
on the choice of the physician at the time of replacement.
Another point of attention might be the relatively limited
number of the ActiValve devices used in the current study
(n = 38, 5.5 % of total) that is based on the high price and
strict criteria for its use.
In conclusion, our study can rule out effects of different
patient groups and allows comparison of device life time
with very limited influence of socioeconomic and reim-
bursement aspects. It shows that the device lifetime of
Provox Vega was better than that of Provox2 and that of
Blom-Singer Classic devices. For further developments on
voice prostheses it should be considered, that devices with
a defined valve opening pressure (Blom-Singer Dual
Valve, Provox Vega and ActiValve) had longer lifetimes
than prostheses with a low and undefined opening pressure
(Blom-Singer Classic and Provox 2).
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